PI3K Inhibitor Kits
Catalog No. K1010
A unique collection of 7 inhibitors for a range of PI3K subtypes
Cited by 17 Publications
7 Customer Reviews
Three-dimensional responses of MCF7/IGF-1R cells to TAM (1 μM), E2 and IGF-1. Compared to parental MCF7 cells (a), MCF7/IGF-1R cells (b) in three-dimensional (3D) culture formed bigger acini in response to IGF-1 stimulation and displayed significant TAM resistance when treated with TAM (1 μM) + E2 + IGF-1, which was removable by kinase inhibitors BMS-536924, U0126 and BEZ235 (c). Cells (10,000/well) were seeded in 96-well plates. Acini were formed on 100% Matrigel and cultured for 14 days in starving medium containing 2% Matrigel and 5% charcoal/dextran-stripped fetal bovine serum with the treatments as indicated. Concentrations used: TAM (1 μM), E2 (1 nM) and IGF-1 (100 ng/mL). Confocal image original magnification, × 20. Red, rhodamine phalloidin (actin). Blue, Hoechst blue stain. Results are representative of two individual experiments.
(A) MCF7 cells pre-treated with 100 nM siRNA for 72 h were re-seeded with normal growth media and grown overnight, then further transfected by 100nM of fresh siRNA. Twenty-(A) four hours after transfection, the cells were further treated with PI-103 for 24 h and the cell lysates were immunoblotted with the indicated antibodies. (B) Breast cancer cells carrying BRCA1 mutations were treated with 1 mM of PI-103 for 24h (left) or increasing amounts of PI-103 for 24 h (right). Cell lysates were analyzed by Western blotting with the indicated antibodies.
After starved in serum-free medium for 24h,A549 cells incubated with the indicated concentrations of A66 for 3h,followed by 20-minute stimolation of 100ng/ml EGF.
After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of AS-605240 for 3h,followed by 15-minute stimolation of 100ng/ml EGF
|Cat.No.||Product Name||Feature||Targets and IC50s||Suggested Solvent||Amount Supplied|
|S1009||BEZ235 (NVP-BEZ235)||A dual ATP-competitive inhibitor of PI3K and mTOR.||4 nM||75 nM||5 nM||7 nM||DMSO 7mg/mL||50 mg|
|S2636||A66||A selective inhibitor of p110α, p110αE545K and p110αH1047R.||32 nM||DMSO 79mg/mL||5 mg|
|S1169||TGX-221||A potent, selective and cell permeable PI3K inhibitor of p110β.||8.5 nM||DMSO 17mg/mL||5 mg|
|S1410||AS-605240||A novel, potent and selective PI3Kγ inhibitor.||8 nM||DMSO 3mg/mL||5 mg|
|S2226||CAL-101 (GS-1101)||A selective class I PI3K inhibitor of p110δ.||2.5 nM||DMSO 83mg/mL||10 mg|
|S1038||PI-103||A potent, cell-permeable and ATP-competitive PI3K family member inhibitor.||8 nM||88 nM||150 nM||48 nM||26 nM||DMSO 24mg/mL||5 mg|
|S2767||3-Methyladenine||A selective autophagy and PI3K inhibitor of Vps34 and PI3Kγ.||60 µM||25 µM||DMSO 3mg/mL||50 mg|
|Formulation||A unique collection of 7 inhibitors for a range of PI3K subtypes supplied as lyophilized powder|
|Container||Screw Cap Micro Tubes of WATSON|